# Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

> **NCT02311569** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 39 (actual)

## Conditions studied

- Myeloproliferative Neoplasm
- Primary Myelofibrosis
- Essential Thrombocythemia
- Polycythemia Vera

## Interventions

- **DRUG:** Mirabegron

## Key facts

- **NCT ID:** NCT02311569
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2019-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02311569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02311569, "Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02311569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*